Canterbury DHB
Treatment is indicated for the following:
The following on their own are NOT indications for treatment:
Asymptomatic, elderly patients may be managed in primary care provided clear instructions for referral are provided. If the patient is referred to the GP, give recommendations for monitoring and re-referral to both the GP and the patient.
Young patients, often taken as <55 years, have a better prognosis than older patients with median survival of 12.5 years, but nevertheless will have considerably shorter life expectancy than age-matched peers. Aggressive treatment with a view to allografting may be appropriate for younger patients and should be discussed early in management.
See Delgado, J. and N. Villamor (2014). "Chronic lymphocytic leukemia in young individuals revisited." Haematologica 99(1): 4-5 and Parikh, S. A., et al. (2014). "Chronic lymphocytic leukemia in young (≤55 years) patients: a comprehensive analysis of prognostic factors and outcomes." Haematologica 99(1): 140-147.
For current trials in CLL, see the Clinical Trials page on the Intranet or phone the Clinical Trials Co-ordinator (ext: 80377).
Topic Code: 5508